Targets › PIK3CB
9 programs from 8 companies in 25 trials: 16 Phase 2, 7 Phase 1, 2 Phase 3; Oncology, Infectious disease, Neurology; next expected readout Dec 2026.
Phosphoinositide-3-kinase (PI3K) phosphorylates phosphatidylinositol derivatives at position 3 of the inositol ring to produce 3-phosphoinositides. Uses ATP and PtdIns(4,5)P2 (phosphatidylinositol 4,5-bisphosphate) to generate phosphatidylinositol 3,4,5-trisphosphate (PIP3). (UniProt, P42338)
Open in Phaseline: the race on PIK3CB, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Celcuity | Gedatolisib Serine/threonine-protein kinase mTOR inhibitor; PI3-kinase class I inhibitor | MTOR, PIK3R1, PIK3CB, PIK3CG, PIK3CA | Phase 3 | Breast Cancer; mCRPC (Metastatic Castration-resistant Prostate Cancer); Endometrial Cancer; TNBC - Triple-Negative Breast Cancer | Dec 2026 |
| ThromBio | TBO-309 PI3Kβ inhibitor that blocks platelet activation, adhesion, and aggregation | PIK3CB | Phase 2 | Ischemic Stroke; Acute Ischemic Stroke | Dec 2026 |
| The First Affiliated Hospital of Xiamen University | Duvalisib Dual phosphoinositide 3-kinase (PI3K) and mitogen-activated protein kinase kinase 4 (MEK) | PIK3CA, PIK3CB, MAP2K4 | Phase 2 | Peripheral T Cell Lymphoma | Dec 2026 |
| National Cancer Institute (NCI) | GSK2636771 PI3K-beta inhibitor | PIK3CB | Phase 2 | Advanced Lymphoma | Dec 2026 |
| Institute of Hematology & Blood Diseases Hospital, China | Linperlisib PI3K inhibitor | PIK3CA, PIK3CB, PIK3D | Phase 2 | Relapsed/Refractory Large B-Cell Lymphoma; Lymphoma, T-Cell | Dec 2026 |
| National Cancer Institute (NCI) | Taselisib (GDC-0032) PI3-kinase class I inhibitor | PIK3R1, PIK3CB, PIK3CG, PIK3CA, PIK3R2 | Phase 2 | Advanced Lymphoma | Mar 2027 |
| Restorbio | Dactolisib (BEZ235) Serine/threonine-protein kinase mTOR inhibitor; PI3-kinase class I inhibitor | MTOR, PIK3R1, PIK3CB, PIK3CG, PIK3CA | Phase 2 | Respiratory Tract Infections; Covid19 | – |
| Eli Lilly | Samotolisib (LY3023414) Serine/threonine-protein kinase mTOR inhibitor; PI3-kinase class I inhibitor | MTOR, PIK3R1, PIK3CB, PIK3CG, PIK3CA | Phase 1 | Breast Neoplasms; Endometrial Cancer | Dec 2026 |
| Sovargen | Paxalisib (SVG103) PI3-kinase class I inhibitor | PIK3R1, PIK3CB, PIK3CG, PIK3CA, PIK3R2 | Phase 1 | Focal Cortical Dysplasia; Primary Central Nervous System Lymphoma; Glioblastoma; CDK Gene Mutation … | Feb 2027 |
Advanced Lymphoma (3) Breast Cancer (2) Endometrial Cancer (2) Relapsed/Refractory Large B-Cell Lymphoma (1) Lymphoma, T-Cell (1) Respiratory Tract Infections (1) Covid19 (1) Ischemic Stroke (1) Acute Ischemic Stroke (1) Peripheral T Cell Lymphoma (1) mCRPC (Metastatic Castration-resistant Prostate Cancer) (1) TNBC - Triple-Negative Breast Cancer (1)
small molecule (8), mixed (1)
National Cancer Institute (NCI) (2) Institute of Hematology & Blood Diseases Hospital, China (1) Restorbio (1) ThromBio (1) The First Affiliated Hospital of Xiamen University (1) Celcuity (1) Eli Lilly (1) Sovargen (1)
PIK3CA (7) PIK3R1 (5) PIK3CG (5) MTOR (3) PIK3R2 (2) PIK3D (1) MAP2K4 (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.